about
Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in NigeriaAcetyl-L-carnitine for patients with hepatic encephalopathyStatistical considerations for stopping systemic lupus erythematosus clinical trials earlierMore efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effectsCurrent controversies in data monitoring for clinical trials.Futility approaches to interim monitoring by data monitoring committees.Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria.A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study)Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?Lung cancer screening with computer aided detection chest radiography: design and results of a randomized, controlled trialStudy protocol for a randomized, double-blind, placebo-controlled trial of a single preoperative steroid dose to prevent nausea and vomiting after thyroidectomy: the tPONV studyA multicenter, randomized, controlled trial of osteopathic manipulative treatment on preterms.A two-stage strategy to accommodate general patterns of confounding in the design of observational studiesTrial Sequential Analysis in systematic reviews with meta-analysisMethodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial.Does caffeine reduce postoperative bowel paralysis after elective laparoscopic colectomy? (CaCo trial): study protocol for a randomized controlled trial.Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).Commentary: Which meta-analyses are conclusive?Statistical challenges in the evaluation of treatments for small patient populations.Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome.Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches.Group-sequential three-arm noninferiority clinical trial designs.A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409.Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.An introduction to multiplicity issues in clinical trials: the what, why, when and how.Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.Local anesthetic wound infusion versus standard analgesia in paediatric post-operative pain control.A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and metGroup-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study.Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
P2860
Q21090716-32882A48-3643-472A-AE12-212745FB93CAQ21144355-C55930AB-663A-47F6-A5C8-C077D0A8ADC8Q24187553-3CB407D6-7A65-4338-B24E-5F89C19A584CQ26774880-C061891F-E1E3-4A7A-A678-A0D553C60369Q28483969-6881CBA9-AE6D-488D-AA45-66564853B96AQ31085612-C7C8FAB5-FFC3-4D8A-858E-4F32C44A0C38Q31085620-600D39CF-071C-44BC-827D-AA7C92F7EB47Q33386027-0DFC56D3-BB5F-4895-A589-BE3829546294Q33647636-D5A46C5C-1037-4FD3-A624-82076218D2C4Q33657188-4D03A01B-E133-4548-A445-8CCFB81E37B0Q34311496-779D4377-9BEF-41AD-921D-3AA2BF79D32DQ34635380-A8106497-43A5-4442-BC55-EE2928A380B6Q34982017-5B2F152E-92B2-43AB-8072-8F59F77ED613Q35606500-EA642850-05E6-43D7-BEF3-48E7A70527C1Q35815956-CE2A30EB-A1E6-4D94-94CD-98F66AC2D976Q36298738-F6E595E0-AEAB-4396-A172-615D65EC61FDQ36309957-4236D162-8D16-455A-94A6-F9816568735EQ36765709-91C8EF14-B587-4E26-82DB-73C87F1527FBQ36812982-14A9AE96-A254-4B30-AA03-4E8FD3478468Q36949347-2854BF74-4BF9-403D-9B6F-3CF7A50E03D8Q37346810-BCC58639-43EC-483C-81A3-F8EE7FCB85F7Q38093778-044F764E-3F71-464F-8DA4-2209E46A6EBFQ38625776-908D98D5-0C9E-45B1-BF8A-D0B06A2E39F2Q38805974-BB3B9AC5-FE62-4120-8D99-0D4EA4AB7A11Q39272947-3DDF261B-3E65-4001-A234-89F55BE91B63Q39896089-732A3C7D-0610-4EFB-91DB-DBDC92762932Q39985904-AC8D1F18-D7F3-4A6C-9132-7849A3E999AEQ40144003-842D1025-98EF-49E1-8E7F-992BCCC22944Q40238661-5A50FA36-1189-4F1D-A115-197BBA57F1D5Q40406803-C4BA6B5A-7204-4393-B031-DE89071079EBQ40655911-45175191-A450-4E3D-8FE1-A4878F6849A1Q40981261-AF6AC003-DB5B-49CF-AAA2-45A9E6B04AE6Q41488053-3554D729-2598-4280-8A36-F973C1EEDFE0Q42104819-40954D35-0587-4EF1-92DF-6D5E6D97C195Q44346771-3B8CF7CC-AC95-4A77-A2BA-8194CD10BB62Q44685863-73A367BC-912B-43F1-A9FE-77ACF7E05F6DQ45024922-860FB916-8C6C-4330-BE1E-31E79028C440Q45734041-91E1ED6E-FC33-46AE-AD2A-C2EB861E46BBQ45797747-ABA23CF7-1CB7-4591-9D26-F6EC5FC2E7ACQ46029341-BA78480F-4036-4EA9-A752-0A34B4E4D484
P2860
description
im Januar 1983 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в 1983
@uk
name
Discrete sequential boundaries for clinical trials
@en
Discrete sequential boundaries for clinical trials
@nl
type
label
Discrete sequential boundaries for clinical trials
@en
Discrete sequential boundaries for clinical trials
@nl
prefLabel
Discrete sequential boundaries for clinical trials
@en
Discrete sequential boundaries for clinical trials
@nl
P356
P1433
P1476
Discrete sequential boundaries for clinical trials
@en
P2093
DAVID L. DEMETS
K. K. GORDON LAN
P304
P356
10.1093/BIOMET/70.3.659
P407
P577
1983-01-01T00:00:00Z